Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration
- 341 Downloads
To evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.
The dry AMD treatment with Rheopheresis trial (ART) was a randomised, controlled clinical study. Patients with the diagnosis of AMD in both eyes, with the study eye presenting dry AMD and soft drusen (the fellow eye had advanced AMD) were randomly assigned in a 1:1 ratio to receive ten Rheopheresis treatments within 17 weeks or to remain untreated. The primary outcome was change in best-corrected ETDRS-visual acuity (mean logMar change) after 7.5 months compared to baseline visual acuity for both groups.
Forty-three eyes of 43 patients (22 treatment and 21 control group) were analysed. The mean baseline BCVA in study eyes was 0.58 in the treatment group and 0.66 in the control group (n.s. p = 0.19). At the primary efficacy endpoint 7.5 months post baseline, there was a statistically significant mean difference of 0.95 ETDRS lines (p = 0.01) between the Rheopheresis and control groups. Nine percent of eyes in the group treated with Rheopheresis gained 2 or more ETDRS lines, as compared with 0% of eyes with no treatment. None of the treated patients had a loss in visual acuity in their study eyes, as compared with 24% of patients without treatment who lost 1 ETDRS line or more; 19% lost 2 ETDRS lines or more. Rheopheresis treatment was safe and well-tolerated.
The results of ART provide further evidence that Rheopheresis is a safe and effective therapeutic option for high-risk patients with dry AMD and no therapeutic alternative. A series of Rheopheresis treatments can improve the natural course of AMD for selected patients.
KeywordsDry AMD Macular degeneration Rheopheresis Apheresis Microcirculation
We thank the following experts for their advice and comments: Prof. Brunner, Prof. Engelmann, Prof. Kirchhof, Prof. Koch, Prof. Nasemann, Prof. Schölzel-Klatt, Prof. Walter.
- 5.Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no.8. Arch Ophthalmol 119(10):1533–1534Google Scholar
- 13.Mösges R, Köberlein J, Heibges A, Erdtracht B, Klingel R, Lehmacher W for the RHEO-ISHL study group (2008) Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial. Eur Arch Otorhinolaryngol Oct 16 [Epub ahead of print]; doi: 10.1007/s00405-008-0823-5
- 15.Widder RA, Farvili E, Reis RGJ, Lüke C, Walter P, Kirchhof B, Borberg H, Brunner R (2002) The treatment of age-related macular degeneration (ARMD) with extracorporeal treatment procedures; a follow-up of four years. Invest Ophthalmol Vis Sci 43: 2906 [ARVO Meeting E-Abstract]Google Scholar
- 16.Swartz M, Rabetoy G (1999) Treatment of non-exudative age-related macular degeneration using membrane differential filtration apheresis (abstract). Invest Ophthalmol Vis Sci 40:319Google Scholar
- 17.Boyer D, MIRA-1 study group (2006) Rheopheresis for dry AMD—efficacy and safety analysis of the pivotal MIRA-1 clinical trial. Invest Ophthalmol Vis Sci 47:2176 [ARVO Meeting E-Abstract]Google Scholar
- 18.Pulido JS, Winters JL, Boyer D (2006) Preliminary analysis of the final multicenter investigation of Rheopheresis for age-related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Opthalmol Soc 104:221–231Google Scholar
- 20.Heibges A, Fassbender C, Erdtracht B, Koch F, Klingel R (2007) Assessment of safety and efficacy of Rheopheresis for dry age-related macular degeneration (AMD) by RheoNet-registry analysis. Nephro-News September 2007:30 (abstract) Google Scholar
- 27.Brunner R, Widder RA, Fischer RA, Walter P, Bartz-Schmidt K-U, Heimann K (1996) Clinical efficacy of haemorheological treatment using plasma exchange, slective adsorption and membrane differential filtration in maculopathy, retinal vein occulosion and uveal effucsion syndrome. Transfus Sci 17:493–498PubMedGoogle Scholar
- 28.Soudavar F, Widder RA, Brunner R, Walter P, Barzt-Schmidt KU, Borberg H, Heimann K (1998) Changes of retinal haemodynamics after elimination of high molecular weight proteins and lipids in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 39:386 [abstract]Google Scholar